Home » SHIRE, U.S.' NEW RIVER TO DEVELOP HYPERACTIVITY TREATMENT
SHIRE, U.S.' NEW RIVER TO DEVELOP HYPERACTIVITY TREATMENT
Shire Pharmaceuticals Group said it signed an agreement to globally develop
and commercialize a new attention-deficit/hyperactivity disorder (ADHD) compound
from New River Pharmaceuticals. Under the non-binding agreement, signed Friday,
the companies will work to develop the compound known as NRP104 that is currently
in advanced clinical trials in the U.S. New River said it expects the treatment
to reach the U.S. market by 2006.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct